Bristol Myers Squibb has developed BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a devastating and life-threatening illness.
BMS-986278 is a promising first-in-class, oral small molecule that acts as an LPA1 antagonist, and it is currently under evaluation as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
This drug aims to target and inhibit LPA1, a receptor associated with the pathogenesis of pulmonary fibrosis. Preclinical in vitro and in vivo studies have shown that antagonising LPA1 may have therapeutic benefits in treating lung injury and fibrosis.
Pulmonary fibrosis is a chronic, life-threatening interstitial lung disease (ILD) characterised by damage and scarring of lung tissue, which adversely affects lung function. The most common type of progressive fibrosing ILD is idiopathic pulmonary fibrosis (IPF), which is characterised by the absence of an identifiable cause. As of 2021, there were over 700,000 adults living with IPF globally.
BMS-986278 represents a promising step forward in addressing the unmet medical need in the treatment of progressive pulmonary fibrosis and IPF.
The FDA's breakthrough therapy designation highlights the significant potential of BMS-986278 as an innovative and groundbreaking treatment that will redefine the standard of care for progressive pulmonary fibrosis.
